OTC: BCAB · Life Sciences · 3 alerts · CIK 1826892
Share price
$1.99Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioAtla, Inc. filings on SEC EDGAR ↗
BioAtla, Inc. reported a significant reduction in net loss to $13.8 million for the first nine months of 2026, compared to $49.8 million in the prior year, primarily driven by $6.8 million in collaboration revenue and a sharp decrease in R&D spending. However, the company's liquidity position is critical, with cash and cash equivalents dropping to $0.6 million as of September 30, 2026, and a total stockholders' deficit of $43.6 million.
BioAtla, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, establishing a facility to sell up to $40.0 million of common stock at the company's option. Shares will be sold at 97% of the lowest daily VWAP over a three-day pricing period following an advance notice. As consideration, the company agreed to pay a $500,000 commitment fee, partially settled through the issuance of warrants for 182,110 shares.
Dr. Eric Sievers resigned as Chief Medical Officer of BioAtla, Inc. effective September 25, 2026, and will transition to a consulting role through June 2027. Additionally, the company reinstated retention bonus programs for CEO Jay M. Short and CFO Christian Vasquez, contingent on achieving financial and capital raising milestones by year-end 2026.